Chlorhexidine/recombinant epidermal growth factor/silver sulfadiazine

Drug Profile

Chlorhexidine/recombinant epidermal growth factor/silver sulfadiazine

Alternative Names: Chlorhexidine/silver sulfadiazine/recombinant epidermal growth factor; Recombinant epidermal growth factor/chlorhexidine/silver sulfadiazine; Recombinant epidermal growth factor/silver sulfadiazine/chlorhexidine; rhEGF/silver sulfadiazine/chlorhexidine gluconate; Silver sulfadiazine/chlorhexidine/recombinant epidermal growth factor; Silver sulfadiazine/recombinant epidermal growth factor/chlorhexidine; SLVRGEN

Latest Information Update: 20 Mar 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bharat Biotech
  • Class Antibacterials; Antiseptics; Growth factors; Heavy metals; Skin disorder therapies; Sulfonamides
  • Mechanism of Action Epidermal growth factor receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Burns

Most Recent Events

  • 31 Dec 2010 Launched for Burns in India (Topical) prior to December 2010
  • 31 Dec 2010 Registered for Burns in India (Topical) prior to December 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top